The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Pi3K inhibitors for CLL
Jacqueline Barrientos, MD, MS, Feinstein Institute for Medical Research, Manhasset, NY, discusses the current use of phosphoinositide 3-kinase (Pi3K) inhibitors in the treatment of chronic lymphocytic leukemia (CLL). Dr Barrientos comments on the use of idelalisib in combination with rituximab, and duvelisib, giving an overview of the safety and tolerability of these drugs and combinations. Dr Barrientos also discusses the use of umbralisib in CLL in combination with rituximab, highlighting an improved safety profile in comparison to other Pi3K inhibitors, and outlines the challenges of using Pi3K inhibitors in earlier settings due to the safety profile in comparison to alternatives such as ibrutinib, acalabrutinib and venetoclax. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
